Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients
Tóm tắt
The risk-benefit balance of pharmacological treatment for children and adolescents with ADHD and the factors that moderate this relationship are unclear. A systematic review and meta-analysis of randomised, placebo-controlled clinical trials (RPCCTs) investigating the efficacy of pharmacological treatment in children or adolescents with ADHD was carried out. Meta-analysis of treatment discontinuation, clinician-, parent- and teacher-rated efficacy and adverse events was performed. The effect of covariates was studied. Sixty-three studies were included. Ten drugs were investigated, with atomoxetine and methylphenidate the most frequently studied. RPCCTs had mostly a short duration (7.9 weeks). All-cause treatment discontinuation was lower with pharmacological treatment than placebo (OR = 0.68). Pharmacological treatment was more efficacious than placebo independently of the rater (clinician, standardised mean difference (SMD) 0.74; parent, SMD = 0.63; or teacher, SMD = 0.75). Evidence of publication bias was found for clinician-rated efficacy, especially in industry-sponsored RPCCT. Psychostimulants showed a higher efficacy and were associated with a better outcome on treatment discontinuation than non-stimulant drugs. Efficacy was smaller in RPCCTs for which a psychiatric comorbid disorder was an inclusion criterion, was larger in studies with a commercial sponsorship and showed a negative association with treatment length. In the short term, pharmacological treatment provides moderate–high symptom relief, is safe and shows lower treatment discontinuation than placebo, suggesting a suitable risk-benefit balance, particularly with psychostimulants. The efficacy is lower in patients with a comorbid psychiatric disorder and should be assessed periodically, as it appears to reduce over time. Publication bias of clinician-rated efficacy in studies with a commercial sponsor is suggested.
Tài liệu tham khảo
Anderson IM, Tomenson BM (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 310:1433–1438
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
Berkey CS, Hoaglin DC, Mosteller F, Colditz GA (1995) A random-effects regression model for meta-analysis. Stat Med 14:395–411
Bolea-Alamañac B, Nutt DJ, Adamou M, Bazire S, Coghill D, Heal D, Müller U, Nash J, Santosh P, Sayal K, Sonuga-Barke E, Young SJ, British Association for Psychopharmacology (2014) Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 28:179–203. doi:10.1177/0269881113519509
Burcu M, Zito JM, Metcalfe L, Underwood H, Safer DJ (2016) Trends in stimulant medication use in commercially insured youths and adults, 2010-2014. JAMA Psychiatry 73:992–993. doi:10.1001/jamapsychiatry.2016.1182
Bushe CJ, Savill NC (2013) Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials. Child Adolesc Psychiatry Ment Health 19:19. doi:10.1186/1753-2000-7-19
Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) (2011) Canadian ADHD practice guidelines, Third edn. CADDRA, Toronto
Charach A, Yeung E, Climans T, Lillie E (2011) Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry 50:9–21. doi:10.1016/j.jaac.2010.09.019
Cochran WC (1954) The combination of estimates from different experiments. Biometrics 10:110–129
Coghill DR, Seth S, Pedroso S, Usala T, Currie J, Gagliano A (2014) Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biol Psychiatry 76:603–615. doi:10.1016/j.biopsych.2013.10.005
Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH (2015) Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 25:611–617. doi:10.1089/cap.2015.0075
Cunill R, Castells X, Tobias A, Capellà D (2015) Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol 29:15–23. doi:10.1177/0269881114544777
Cunill R, Castells X, Tobias A, Capellà D (2016) Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients. Psychopharmacology 233:187–197. doi:10.1007/s00213-015-4099-3
Daley D, Birchwood J (2010) ADHD and academic performance: why does ADHD impact on academic performance and what can be done to support ADHD children in the classroom? Child Care Health Dev 36:455–464. doi:10.1111/j.1365-2214.2009.01046.x
Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015) Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 385:2190–2196. doi:10.1016/S0140-6736(14)61684-6
Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A (2002) Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31:140–149
Faraone SV, Glatt SJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71:754–763. doi:10.4088/JCP.08m04902pur
Feldman HM, Reiff MI (2014) Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 370:838–846. doi:10.1056/NEJMcp1307215
Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E, European Guidelines Group (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20:17–37. doi:10.1007/s00787-010-0140-6
Harpin VA (2005) The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 90(Suppl 1):i2–i7. doi:10.1136/adc.2004.059006
Higgins JPT, Green S (2011a) The Cochrane Collaboration tool for assessing risk of bias. In Cochrane handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration Available from www. cochrane-handbook.org
Higgins JPT, Green S (2011b) How to include multiple groups from one study. In Higgins JPT, Green S (eds), Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration Available from www. cochrane-handbook.org
Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. doi:10.1136/bmj.327.7414.557
Hirota T, Schwartz S, Correll CU (2014) Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 53:153–173. doi:10.1016/j.jaac.2013.11.009
Hoza B (2007) Peer functioning in children with ADHD. J Pediatr Psychol 32:655–663. doi:10.1093/jpepsy/jsm024
Jensen CM, Steinhausen HC (2015) Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study. Atten Defic Hyperact Disord 7:27–38. doi:10.1007/s12402-014-0142-1
Jerome L, Segal A, Habinski L (2006) What we know about ADHD and driving risk: a literature review, meta-analysis and critique. J Can Acad Child Adolesc Psychiatry 15:105–125
Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343:1290–1297. doi:10.1056/NEJM200011023431802
Langley K, Fowler T, Ford T, Thapar AK, van den Bree M, Harold G, Owen MJ, O'Donovan MC, Thapar A (2010) Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder. Br J Psychiatry 196:235–240. doi:10.1192/bjp.bp.109.066274
Larson K, Russ SA, Kahn RS, Halfon N (2011) Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 127:462–470. doi:10.1542/peds.2010-0165
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071. doi:10.1016/S0140-6736(12)60239-6
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223. doi:10.1056/NEJMoa051688
Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017) Industry sponsorship and research outcome. Cochrane Database Syst Rev 2 doi: 10.1002/14651858.MR000033.pub3.
Mannuzza S, Klein RG, Moulton JL (2008) Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records. Psychiatry Res 160:237–246. doi:10.1016/j.psychres.2007.11.003
McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 163:1531–1541. doi:10.1176/ajp.2006.163.9.1531
Mick E, McManus DD, Goldberg RJ (2013) Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol 23:534–541. doi:10.1016/j.euroneuro.2012.06.011
Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L, Abikoff HB, Elliott GR, Greenhill LL, Newcorn JH, Wells KC, Wigal T, Gibbons RD, Hur K, Houck PR, MTA Cooperative Group (2009) The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48:484–500. doi:10.1097/CHI.0b013e31819c23d0
MTA Cooperative Group (2004) National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 113:762–769
National Institute for Health and Clinical Excellence (NICE) (2008) Attention deficit hyperactivitydisorder. Diagnosis and management of ADHD in children, young people and adults. Clinical guidelines CG72 (Last updated February 2016)
Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D, Atomoxetine/Methylphenidate Comparative Study Group (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 165:721–730. doi:10.1176/appi.ajp.2007.05091676
Nigg JT (2013) Attention-deficit/hyperactivity disorder and adverse health outcomes. Clin Psychol Rev 33:215–228. doi:10.1016/j.cpr.2012.11.005
No authors (2015) Drugs for ADHD. Med Lett Drugs Ther 57:37–40
Nordic CT, Cochrane Centre TCC (2014) ReviewManager (RevMan). Copenhagen
Otasowie J, Castells X, Ehimare UP, Smith CH (2014) Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 19:CD006997. doi:10.1002/14651858.CD006997.pub2
Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT (2009) Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 361:777–786. doi:10.1056/NEJMoa0810635
Perrin JM, Friedman RA, Knilans TK, Black Box Working Group, Section on Cardiology and Cardiac Surgery (2008) Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122:451–453. doi:10.1542/peds.2008-1573
Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, Vohra S (2016) Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2:CD009996. doi:10.1002/14651858.CD009996.pub2
Ruggiero S, Clavenna A, Reale L, Capuano A, Rossi F, Bonati M (2014) Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis. Eur Neuropsychopharmacol 24:1578–1590. doi:10.1016/j.euroneuro.2014.08.001
Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA, CATIE-AD Study Group (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355:1525–1538. doi:10.1056/NEJMoa061240
Schwartz S, Correll CU (2014) Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 53:174–187. doi:10.1016/j.jaac.2013.11.005
Seixas M, Weiss M, Müller U (2012) J Psychopharmacol 26:753–765. doi:10.1177/0269881111412095
StataCorp (2011) Stata statistical software: release 12 [computer program] (2011). StataCorp, College Station
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C (2015) Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev 11:CD009885. doi:10.1002/14651858.CD009885.pub2
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29:15–31. doi:10.1093/oxfordjournals.schbul.a006986
Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S (2011) ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128:1007–1022. doi:10.1542/peds.2011-2654
Swanson JM, Volkow ND (2008) Increasing use of stimulants warns of potential abuse. Nature 453:586. doi:10.1038/453586a
Tamminga HG, Reneman L, Huizenga HM, Geurts HM (2016) Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis. Psychol Med 46:1791–1807. doi:10.1017/S0033291716000350
Thomas R, Sanders S, Doust J, Beller E, Glasziou P (2015) Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics 135:994–1001. doi:10.1542/peds.2014-3482
Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, Perou R, Blumberg SJ (2014) Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry 53:34–46. doi:10.1016/j.jaac.2013.09.001
Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011) Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36:375–389. doi:10.1038/npp.2010.192